Heribert Arnhof

2.0k total citations
8 papers, 69 citations indexed

About

Heribert Arnhof is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Heribert Arnhof has authored 8 papers receiving a total of 69 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 3 papers in Oncology and 2 papers in Immunology. Recurrent topics in Heribert Arnhof's work include Adenosine and Purinergic Signaling (1 paper), Sarcoma Diagnosis and Treatment (1 paper) and Protein Kinase Regulation and GTPase Signaling (1 paper). Heribert Arnhof is often cited by papers focused on Adenosine and Purinergic Signaling (1 paper), Sarcoma Diagnosis and Treatment (1 paper) and Protein Kinase Regulation and GTPase Signaling (1 paper). Heribert Arnhof collaborates with scholars based in Austria, Italy and Germany. Heribert Arnhof's co-authors include Marco H. Hofmann, Rob Leurs, Obbe P. Zuiderveld, Harald Engelhardt, Eric Haaksma, Michael P. Sanderson, Norbert Kraut, Moriz Mayer, Iwan J. P. de Esch and Jürgen Moll and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Cancer Research and Journal of Medicinal Chemistry.

In The Last Decade

Heribert Arnhof

8 papers receiving 69 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Heribert Arnhof Austria	5	46	25	10	9	9	8	69
Min Qiao China	5	44 1.0×	8 0.3×	17 1.7×	3 0.3×	14 1.6×	6	101
Mark J. Chicarelli United States	5	61 1.3×	10 0.4×	12 1.2×	24 2.7×	3 0.3×	6	78
Matthew D. Falk United States	6	106 2.3×	47 1.9×	18 1.8×	5 0.6×	2 0.2×	6	132
Su‐Chen Huang United States	4	39 0.8×	21 0.8×	31 3.1×	13 1.4×	6 0.7×	4	81
Hiu Yan Lam Singapore	6	31 0.7×	30 1.2×	7 0.7×	3 0.3×	6 0.7×	13	107
Astrid Petersmann Germany	4	32 0.7×	7 0.3×	7 0.7×	7 0.8×	11 1.2×	10	65
Rachel Newman United States	4	26 0.6×	20 0.8×	11 1.1×	6 0.7×	6 0.7×	4	59
Kelsey Pendleton United States	3	52 1.1×	28 1.1×	18 1.8×	1 0.1×	8 0.9×	4	87
René Pfeifle Germany	4	61 1.3×	59 2.4×	11 1.1×	5 0.6×	3 0.3×	8	110
Ilenia Cammarata Italy	4	23 0.5×	29 1.2×	16 1.6×	4 0.4×	6 0.7×	7	75

Countries citing papers authored by Heribert Arnhof

Since Specialization

Citations

This map shows the geographic impact of Heribert Arnhof's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heribert Arnhof with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heribert Arnhof more than expected).

Fields of papers citing papers by Heribert Arnhof

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Heribert Arnhof. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heribert Arnhof. The network helps show where Heribert Arnhof may publish in the future.

Co-authorship network of co-authors of Heribert Arnhof

This figure shows the co-authorship network connecting the top 25 collaborators of Heribert Arnhof. A scholar is included among the top collaborators of Heribert Arnhof based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Heribert Arnhof. Heribert Arnhof is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

Baltanás, Fernando C., Rósula García‐Navas, Enrico Patrucco, et al.. (2025). SOS1 inhibitor BI-3406 shows in vivo antitumor activity akin to genetic ablation and synergizes with a KRAS ^G12D inhibitor in KRAS LUAD. Proceedings of the National Academy of Sciences. 122(11). e2422943122–e2422943122. 1 indexed citations

Jiménez, Diego García, Giuseppe Ermondi, Zuzana Jandová, et al.. (2025). Linker Methylation as a Strategy to Enhance PROTAC Oral Bioavailability: Insights from Molecular Properties and Conformational Analysis. Journal of Medicinal Chemistry. 68(15). 16666–16677. 1 indexed citations

Jackson, Mark, Niousha Ahmari, Jianqiang Wu, et al.. (2023). Combining SOS1 and MEK Inhibitors in a Murine Model of Plexiform Neurofibroma Results in Tumor Shrinkage. Journal of Pharmacology and Experimental Therapeutics. 385(2). 106–116. 8 indexed citations

Kuttruff, Christian A., Martin Fleck, Sebastian Carotta, et al.. (2023). Discovery of BI 7446: A Potent Cyclic Dinucleotide STING Agonist with Broad-Spectrum Variant Activity for the Treatment of Cancer. Journal of Medicinal Chemistry. 66(14). 9376–9400. 12 indexed citations

Sanderson, Michael P., Marco H. Hofmann, Pilar Garin‐Chesa, et al.. (2017). The IGF1R/INSR Inhibitor BI 885578 Selectively Inhibits Growth of IGF2-Overexpressing Colorectal Cancer Tumors and Potentiates the Efficacy of Anti-VEGF Therapy. Molecular Cancer Therapeutics. 16(10). 2223–2233. 22 indexed citations

Hofmann, Marco H., Harald Engelhardt, Sebastian Carotta, et al.. (2017). Abstract 4630: Development of selective and potent CDK8 inhibitors that increase NK cell activity, which translates in tumor surveillance. Cancer Research. 77(13_Supplement). 4630–4630. 1 indexed citations

Engelhardt, Harald, Sabine Schultes, Chris de Graaf, et al.. (2013). Bispyrimidines as Potent Histamine H₄ Receptor Ligands: Delineation of Structure–Activity Relationships and Detailed H₄ Receptor Binding Mode. Journal of Medicinal Chemistry. 56(11). 4264–4276. 10 indexed citations

Engelhardt, Harald, Iwan J. P. de Esch, Daniel Kühn, et al.. (2012). Detailed structure–activity relationship of indolecarboxamides as H4 receptor ligands. European Journal of Medicinal Chemistry. 54. 660–668. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact